Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 16;12:1756286419892078. doi: 10.1177/1756286419892078

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — (a) Correlation of the unified dosis (mean dose of the last 10 injections) used for the treatment of the ELISA-positive patients (abscissa) with the paralysis time measured in the MHDA (ordinate). The correlation is significant (p < 0.027), patients with longer paralysis times were treated with higher doses. (b) Correlation of the pain subscore of the CDQ24 questionnaire of the ELISA-positive patients (abscissa) with the paralysis time measured in the MHD-assay (ordinate). The correlation is significant (p < 0.012), patients with longer paralysis times suffered from more intensive pain.

ELISA, enzyme-linked immunosorbent assay; MHDA, mouse hemi-diaphragm assay.